2024-09-21 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a research-based biopharmaceutical company that develops, manufactures, and commercializes a wide range of pharmaceuticals.

**1. Performance Analysis:**

* **Cumulative Return:** ABBV has delivered a cumulative return of 152.05% compared to the S&P 500 (VOO) which has returned 133.16%. 
* **Relative Performance:** ABBV has outperformed the S&P 500, with a current relative performance of 18.89%. This translates to a relative performance ranking of 60.18% based on historical data. This means ABBV has performed better than the S&P 500 in 60.18% of the time over the historical period.

**2. Recent Price Action:**

* **Closing Price:** $193.38
* **5-Day Moving Average:** $193.80
* **20-Day Moving Average:** $195.42
* **60-Day Moving Average:** $184.98
* **Analysis:** The current price is below both the 5-day and 20-day moving averages, indicating a potential short-term downward trend. However, the price is above the 60-day moving average, suggesting a possible long-term uptrend.

**3. Technical Indicators:**

* **RSI:** 46.32 (Neutral)
* **PPO:** -0.5 (Neutral)
* **Delta_Previous_Relative_Divergence:** -7.92 (Short-term downward trend)
* **Expected Return:** 24.9% (This represents a potential maximum return on investment over a 5-10 year period)

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

**Analysis:** ABBV has consistently exceeded earnings expectations in recent quarters. The latest earnings report for Q2 2024 showed an EPS of 2.65, surpassing the expected EPS of 2.57. This positive trend suggests strong underlying business performance and a potential for continued growth.

**5. Overall Analysis:**

ABBV has demonstrated strong historical performance, outperforming the S&P 500. However, recent price action suggests some short-term weakness. Technical indicators are currently neutral, but the recent relative divergence suggests a potential short-term downward trend. Strong earnings performance and a positive outlook continue to support ABBV as a potential long-term investment. 

**6. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  It is essential to conduct thorough research and consult with a qualified financial professional before making any investment decisions. 
